|
TSTIF
|
I just came upon the short interest for TOS as of March 15. It is up only a...
|
|
TSTIF
|
(And, of course, the 'iceberg' will disrupt the market for players...
|
|
TSTIF
|
Yes. Brilliant presentation and discussion! Mention was even made at the end...
|
|
TSTIF
|
The Roth presentation is about to begin, but the slide are available on the...
|
|
TSTIF
|
Lematou, I think your analysis is right on: while the pr states "similar...
|
|
TSTIF
|
Interesting that Desjardins suggested to buy on weakness, implying a possible...
|
|
TSTIF
|
FDA has been a difficult bureaucracy to deal with, obviously, but the process...
|
|
TSTIF
|
Again, couldn't agree more, GoPats. This is only good, constructive news....
|
|
TSTIF
|
Again, very good progress toward establishing the VP4 as the new standard of...
|
|
TSTIF
|
$10 CDN is a very realistic sp. The sky looks clear and bright blue on all...
|
|
TSTIF
|
Couldn't agree more, GoPats. But, for an institution, or anyone, to start...
|
|
TSTIF
|
Yes, I agree extended claims world wide will very likely be validated, based...
|
|
TSTIF
|
I beg to differ. When I asked at the last cc November 4, 2015 about TSO3...
|
|
TSTIF
|
P.S., Just had a moment to check the new presentation. The slides that were...
|
|
TSTIF
|
Yep!!! Just a little premature .... ? Perhaps, confirmation and...
|
|
TSTIF
|
While some of us have been waiting for clarity on TSO3 claims approval for...
|
|
TSTIF
|
Yes. Thanks. The annual meeting should have results of fiscal 1st quarter...
|
|
TSTIF
|
Meaningless, unless MS is trying to make the spurious argument to IRROC that...
|
|
T.EDV
|
at Canaccord increased from $13 to $15.50 at Raymond James from $11.50 to $14...
|
|
TSTIF
|
Excellent point, fraser. These shorts may still very well be tied to the...
|